CellPro loses patent infringement case:
This article was originally published in Clinica
Executive Summary
A federal district court has awarded $2.3 million in damages to Johns Hopkins, Baxter International and Becton Dickinson against CellPro. The court found that CellPro had infringed two patents involving CD34 monoclonal antibodies and purified stem cells (see Clinica No 713, p 15). The jury's finding allows Johns Hopkins, Baxter and Becton to seek from the court damages of up to triple the amount. CellPro intends to appeal.